Stephen V Liu, Tom Powles, MD Anderson, ASCO, and multiple oncologists amplify approvals, resistance case reports, trial design tweaks, and meeting previews as a steady multi-account theme.
The @US_FDA has approved breuxcabtagene autoleucel
Deprioritization of zelenectide pevedotin
CURB2 Ph3 RCT now allows those assigned to SOC to have the flexibility
Still learning about resistance to KRAS inhibitors.
Only one week away! Register now for the 2026 Texas Lung Cancer Conference
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare